GleamWall
中文EN

SLGL Sol-Gel Technologies Ltd.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1684693 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY68.0%
TTM net income YoY42.1%
TTM EPS YoY42.2%
Revenue 3-yr CAGR70.9%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-38.9%
Net margin-31.6%
FCF margin1.4%
EBITDA margin-38.3%

Returns

ROE-23.7%
ROA-18.6%
ROIC (approx.)-56.3%
Asset turnover0.59x

Leverage & solvency

Liabilities / assets23.8%
Debt / equity0.00x
Current ratio4.37x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-0.05x
Accruals ratio-19.6%
Payout ratio—
Capex / revenue0.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2025Q22025-06-302024Q22024-06-302023Q22023-06-302022Q22022-06-302021Q22021-06-302020Q22020-06-302019Q22019-06-302018Q22018-06-30
Income statement
Revenue$17.26M$5.43M$594,000$3.52M$928,000$1.13M$7.79M$49,000
R&D expense$4.65M$2.44M$5.31M$2.38M$6.93M$6.45M$11.44M$5.82M
SG&A expense$1.39M$1.37M$1.81M$1.60M$2.04M$2.23M$1.64M$1.52M
Operating income$11.23M$1.62M-$6.53M-$463,000-$8.04M-$7.55M-$5.29M-$7.29M
Net income$11.61M$1.98M-$5.97M-$134,000-$8.03M-$7.07M-$4.93M-$6.91M
EPS (basic)4.170.71-0.220.010.350.310.260.36
EPS (diluted)4.170.71-0.220.010.350.310.260.36
Weighted avg. shares (diluted)2.79M2.79M27.66M23.13M23.03M22.92M18.95M18.95M
Balance sheet
Cash & equivalents$10.22M$11.55M$15.62M$5.76M$11.15M$5.44M$14.39M$18.24M
Short-term investments$14.05M$14.91M$17.86M$9.85M$6.83M$40.68M$35.52M—
Receivables$10.04M$6.06M$2.21M$10.18M$956,000$1.17M$7.83M—
Current assets$36.26M$38.28M$51.59M$48.48M$41.39M$68.69M$58.83M—
PP&E, net$162,000$305,000$569,000$826,000$1.40M$2.20M$2.45M—
Total assets$39.31M$42.01M$55.10M$54.98M$46.41M$74.63M$63.38M—
Current liabilities$4.96M$5.20M$5.67M$3.23M$5.16M$6.91M$7.36M—
Total liabilities$7.42M$7.10M$6.81M$4.63M$7.16M$9.11M$8.64M—
Shareholders' equity$31.88M$34.90M$48.30M$50.35M$39.25M$65.52M$54.74M$81.55M
Shares outstanding2.79M27.86M27.81M23.13M23.03M23.00M18.95M—
Cash flow statement
Operating cash flow————————
Stock-based compensation$100,000$275,000$498,000$352,000$213,000$315,000——

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.